IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v21y2020i8d10.1007_s10198-020-01229-1.html
   My bibliography  Save this article

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

Author

Listed:
  • J. Pöhlmann

    (Ossian Health Economics and Communications)

  • K. Norrbacka

    (Eli Lilly Finland)

  • K. S. Boye

    (Eli Lilly and Company)

  • W. J. Valentine

    (Ossian Health Economics and Communications)

  • H. Sapin

    (Lilly France)

Abstract

Background Health economic evaluations require cost data as key inputs. Many countries do not have standardized reference costs so costs used often vary between studies, thereby reducing transparency and transferability. The present review provided a comprehensive overview of cost sources and suggested unit costs for France, Germany and Italy, to support health economic evaluations in these countries, particularly in the field of diabetes. Methods A literature review was conducted across multiple databases to identify published unit costs and cost data sources for resource items commonly used in health economic evaluations of antidiabetic therapies. The quality of unit cost reporting was assessed with regard to comprehensiveness of cost reporting and referencing as well as accessibility of cost sources from published cost-effectiveness analyses (CEA) of antidiabetic medications. Results An overview of cost sources, including tariff and fee schedules as well as published estimates, was developed for France, Germany and Italy, covering primary and specialist outpatient care, emergency care, hospital treatment, pharmacy costs and lost productivity. Based on these sources, unit cost datasets were suggested for each country. The assessment of unit cost reporting showed that only 60% and 40% of CEAs reported unit costs and referenced them for all pharmacy items, respectively. Less than 20% of CEAs obtained all pharmacy costs from publicly available sources. Conclusions This review provides a comprehensive account of available costs and cost sources in France, Germany and Italy to support health economists and increase transparency in health economic evaluations in diabetes.

Suggested Citation

  • J. Pöhlmann & K. Norrbacka & K. S. Boye & W. J. Valentine & H. Sapin, 2020. "Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1179-1196, November.
  • Handle: RePEc:spr:eujhec:v:21:y:2020:i:8:d:10.1007_s10198-020-01229-1
    DOI: 10.1007/s10198-020-01229-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-020-01229-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-020-01229-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Adam D M Briggs & Peter Scarborough & Jane Wolstenholme, 2018. "Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-14, May.
    2. José Leal & Stefania Manetti & James Buchanan, 2018. "The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study," PharmacoEconomics, Springer, vol. 36(10), pages 1263-1272, October.
    3. Bernard Charbonnel & Dominique Simon & Jean Dallongeville & Isabelle Bureau & Sylvie Dejager & Laurie Levy-Bachelot & Julie Gourmelen & Bruno Detournay, 2018. "Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis," PharmacoEconomics - Open, Springer, vol. 2(2), pages 209-219, June.
    4. A. Marcellusi & R. Viti & A. Mecozzi & F. Mennini, 2016. "The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(2), pages 139-147, March.
    5. Hildegard Seidl & Matthias Hunger & Reiner Leidl & Christa Meisinger & Rupert Wende & Bernhard Kuch & Rolf Holle, 2015. "Cost-effectiveness of nurse-based case management versus usual care for elderly patients with myocardial infarction: results from the KORINNA study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(6), pages 671-681, July.
    6. M François & T Hanslik & B Dervaux & Y Le Strat & C Souty & S Vaux & S Maugat & C Rondet & M Sarazin & B Heym & B Coignard & L Rossignol, 2016. "The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey," Post-Print hal-01365246, HAL.
    7. A. Marcellusi & R. Viti & A. Mecozzi & F. Mennini, 2016. "The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(2), pages 139-147, March.
    8. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    9. William J. Valentine & Kate Brunt & Kristina S. Boye & Richard F. Pollock, 2018. "Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation," Applied Health Economics and Health Policy, Springer, vol. 16(3), pages 357-366, June.
    10. Anthony J Culyer, 2018. "Cost, context and decisions in Health Economics and cost-effectiveness analysis," Working Papers 154cherp, Centre for Health Economics, University of York.
    11. Melanie J. Davies & Divina Glah & Barrie Chubb & Gerasimos Konidaris & Phil McEwan, 2016. "Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting," PharmacoEconomics, Springer, vol. 34(9), pages 953-966, September.
    12. Grégoire Lagasnerie & Anne-Sophie Aguadé & Pierre Denis & Anne Fagot-Campagna & Christelle Gastaldi-Menager, 2018. "The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 189-201, March.
    13. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    14. Grupp, Helen & König, Hans-Helmut & Konnopka, Alexander, 2016. "Health care utilisation and costs in the general population in Germany," Health Policy, Elsevier, vol. 120(2), pages 159-169.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Chris Sampson’s journal round-up for 26th October 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-10-26 12:00:03

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. François-Olivier Baudot & Anne-Sophie Aguadé & Thomas Barnay & Christelle Gastaldi-Ménager & Anne Fagot-Campagna, 2019. "Impact of type 2 diabetes on health expenditure: estimation based on individual administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 657-668, July.
    2. Matthew Franklin & James Lomas & Gerry Richardson, 2020. "Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations," PharmacoEconomics, Springer, vol. 38(7), pages 665-681, July.
    3. Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín, 2020. "A general framework for classifying costing methods for economic evaluation of health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 529-542, June.
    4. Rodríguez-Sánchez, Beatriz & Cantarero-Prieto, David, 2019. "Socioeconomic differences in the associations between diabetes and hospital admission and mortality among older adults in Europe," Economics & Human Biology, Elsevier, vol. 33(C), pages 89-100.
    5. Maxwell Ogochukwu Adibe & Chibueze Anosike & Sunday Odunke Nduka & Abdulmuminu Isah, 2018. "Evaluation of Health Status of Type 2 Diabetes Outpatients Receiving Care in a Tertiary Hospital in Nigeria," PharmacoEconomics - Open, Springer, vol. 2(3), pages 337-345, September.
    6. Paola Rucci & Vera Maria Avaldi & Claudio Travaglini & Cristina Ugolini & Elena Berti & Maria Luisa Moro & Maria Pia Fantini, 2020. "Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis," PharmacoEconomics - Open, Springer, vol. 4(1), pages 181-190, March.
    7. James Lomas & Stephen Martin & Karl Claxton, 2018. "Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13," Working Papers 158cherp, Centre for Health Economics, University of York.
    8. Mathilde François & Barbara Clais & Thierry Blanchon & Cécile Souty & Thomas Hanslik & Louise Rossignol, 2018. "Factors associated with the duration of symptoms in adult women with suspected cystitis in primary care," PLOS ONE, Public Library of Science, vol. 13(7), pages 1-13, July.
    9. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.
    10. Sonsoles Fuentes & Emmanuel Cosson & Laurence Mandereau-Bruno & Anne Fagot-Campagna & Pascale Bernillon & Marcel Goldberg & Sandrine Fosse-Edorh, 2019. "Identifying diabetes cases in health administrative databases: a validation study based on a large French cohort," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(3), pages 441-450, April.

    More about this item

    Keywords

    Cost; Cost-effectiveness; Diabetes; France; Germany; Italy;
    All these keywords.

    JEL classification:

    • D61 - Microeconomics - - Welfare Economics - - - Allocative Efficiency; Cost-Benefit Analysis
    • I10 - Health, Education, and Welfare - - Health - - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:21:y:2020:i:8:d:10.1007_s10198-020-01229-1. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: . General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.